SIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical

Stock News

Aug 15

SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with Type 2 diabetes. Additionally, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage.

According to reports, semaglutide injection is a once-weekly long-acting GLP-1 receptor agonist (GLP-1RA) that activates GLP-1 receptors to enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, thereby achieving blood glucose reduction effects. Meanwhile, semaglutide can reduce appetite and food intake, helping patients decrease caloric consumption and achieve weight reduction.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1113120887"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113120887\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113120887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 19:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113120887","market":"fut","top_or_hot":-1,"title":"SIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical","media":"Stock News","content":"<p>SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with Type 2 diabetes. Additionally, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage.</p>\n<p>According to reports, semaglutide injection is a once-weekly long-acting GLP-1 receptor agonist (GLP-1RA) that activates GLP-1 receptors to enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, thereby achieving blood glucose reduction effects. Meanwhile, semaglutide can reduce appetite and food intake, helping patients decrease caloric consumption and achieve weight reduction.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-15 19:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with Type 2 diabetes. Additionally, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage.</p>\n<p>According to reports, semaglutide injection is a once-weekly long-acting GLP-1 receptor agonist (GLP-1RA) that activates GLP-1 receptors to enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, thereby achieving blood glucose reduction effects. Meanwhile, semaglutide can reduce appetite and food intake, helping patients decrease caloric consumption and achieve weight reduction.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"","article_id":"1113120887","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113120887","pubTimestamp":1755258019,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1593":"医美概念股","BK1600":"工业大麻","BK1515":"抗疫概念","00460":"四环医药","BK1191":"制药"},"translate_title":"四环医药(00460)：NMPA受理惠升生物制药研发的司美格鲁肽注射液上市申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with Type 2 diabetes. Additionally, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage.\nAccording to reports, semaglutide injection is a once-weekly long-acting GLP-1 receptor agonist (GLP-1RA) that activates GLP-1 receptors to enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, thereby achieving blood glucose reduction effects. Meanwhile, semaglutide can reduce appetite and food intake, helping patients decrease caloric consumption and achieve weight reduction.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}